Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 163Specimen Handling 135enzalutamide 126Nivolumab 124Gemcitabine 99Docetaxel 96Radiosurgery 92Prednisone 85Androgen Antagonists 82Abiraterone Acetate 81Radiotherapy 75apalutamide 68Cisplatin 65darolutamide 63Ipilimumab 63Biopsy 60abiraterone 58Carboplatin 56cabozantinib 55Leuprolide 53enfortumab vedotin 49Radiation 48Pluvicto 45Standard of Care 44atezolizumab 40Surveys and Questionnaires 39acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
5-aminolevulinic acid hexyl ester × Genitourinary × 1 year × Clear all
NCT05962541 2025-12-31

CUT-less

University of Roma La Sapienza

Phase 4 Recruiting
327 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT02660645 2025-12-18

BLCCR

Photocure

Recruiting
4,400 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06525571 2025-11-18

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Johns Hopkins University

Phase 3 Recruiting
200 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡